Anzeige
Mehr »
Login
Samstag, 28.03.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrEMA grants orphan drug designation to AlloVir's Viralym-M
FrFDA approves Bristol Myers Squibb's ZEPOSIA oral treatment for relapsing forms of multiple sclerosis
FrNovartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease
DoInfinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer
DoAlnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
DoXencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19
MiAveXis' Zolgensma gene therapy yields desired results in SMA trials
DiHoth Therapeutics announces agreement to joint development for a self-assembling vaccine (SAV) for the potential prevention of coronavirus
DiAbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML
DiFDA approves COVACTA trial for RA drug Actemra in COVID-19 patients
MoViiV Healthcare secures Canadian approval for HIV drug regimen CABENUVA
MoDesign Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders
MoAmneal accelerates distribution and production of Hydroxychloroquine Sulfate to meet potential needs of COVID-19 patients nationwide
MoFeinstein Institutes begins three clinical trials for COVID-19 patients
20.03.Novartis receives Japanese approval for Zolgensma in spinal muscular atrophy
20.03.FDA approves new treatment for paediatric patients with any strain of Hepatitis C
20.03.Roche to begin Actemra/RoActemra trial with COVID-19 pneumonia patients
19.03.Pfizer's abrocitinib meets co-primary efficacy endpoints in phase 3 AD trial
19.03.Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran
19.03.Dicerna receives orphan drug designation from FDA for DCR-A1AT to treat alpha-1 antitrypsin deficiency
19.03.Entos to develop Fusogenix DNA vaccine to prevent COVID-19 infections
18.03.Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial
18.03.RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration
18.03.Merck announces top-line results from phase 3 trials evaluating Gefapixant
18.03.Pfizer, BioNTech collaborate to develop vaccine for COVID-19